Oncology (all articles)
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022
M-A | Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions.
11 Aug, 2022 | 11:51h | UTCCommentary: Can Folic Acid Halt or Reverse Progression of Gastric Precancerous Conditions? – Medscape (free registration required)
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
RCT | Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus.
9 Aug, 2022 | 12:24h | UTCCommentary: Esophagus-Sparing Radiation Fails QOL Test in Lung Cancer— Esophageal-specific quality of life no better, but treatment reduced symptomatic esophagitis – MedPage Today (free registration required)
Commentary on Twitter
PROACTIVE was a phase 3 RCT of 90 pts with incurable lung cancer treated with esophageal sparing IMRT vs. standard palliative RT. ES-IMRT did not improve FACT-E ECS quality of life scores at 2wks but reduced grade≥2 esophagitis (24% vs. 2%). https://t.co/ExIp22WBPe #RadOnc #LCSM pic.twitter.com/lX8lD4Duja
— JAMA Oncology (@JAMAOnc) February 24, 2022
Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
9 Aug, 2022 | 12:20h | UTC
Commentary on Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022
Systematic Review | Impact of low‐dose computed tomography screening on lung cancer‐related mortality.
8 Aug, 2022 | 11:52h | UTCSummary: Impact of computed tomography (CT) on lung cancer screening – Cochrane Library
Related:
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment.
5 Aug, 2022 | 14:43h | UTCNews Release: HPV vaccination alongside surgery for cervical lesions may reduce risk of further disease – BMJ Newsroom
Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.
5 Aug, 2022 | 14:37h | UTC
Systematic Review | Endometrial cancer and BRCA mutations.
5 Aug, 2022 | 14:09h | UTCEndometrial Cancer and BRCA Mutations: A Systematic Review – Journal of Clinical Medicine
RCT | Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
5 Aug, 2022 | 13:50h | UTCLenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer — In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone – MedPage Today (free registration required)
Gastric cancer | ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
4 Aug, 2022 | 14:14h | UTC
Esophageal cancer | ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
4 Aug, 2022 | 14:12h | UTC
RCT | Therapeutic value of sentinel lymph node biopsy in patients with melanoma.
4 Aug, 2022 | 14:05h | UTCTherapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (free for a limited period)
Mucinous rectal cancers: clinical features and prognosis in a population-based cohort.
4 Aug, 2022 | 13:17h | UTCMucinous rectal cancers: clinical features and prognosis in a population-based cohort – BJS Open
Commentary on Twitter
https://twitter.com/BjsOpen/status/1521784196255027201
M-A | Repeat hepatic resection vs. percutaneous ablation for the treatment of recurrent hepatocellular carcinoma.
4 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Recurrent #HCC after resection: re-resect or ablate?
📰#systematicreviewRedo-Resection has:
– ⏫Morbidity 17% vs 3%
– ⏫ recurrence free survival (HR 0.79)
– ⚖️ overall survival (HR 0.93 (0.83-1.04))https://t.co/WWwsHNkNQ9#SoMe4Surgery #some4hpb@SEIQuirurgica @asgbi pic.twitter.com/h4apdpY7eh— BJS Open (@BjsOpen) May 6, 2022
Guideline | Androgen deprivation therapy: adverse events and management strategies.
3 Aug, 2022 | 14:15h | UTC
RCT | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy.
3 Aug, 2022 | 14:02h | UTCSintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Sintilimab plus #bevacizumab #biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell #lungcancer #NSCLC who progressed on EGFR TKI therapy: first interim results from ORIENT-31 https://t.co/5VwmLCcGW5 pic.twitter.com/RWeeyfuC6i
— The Lancet Oncology (@TheLancetOncol) August 2, 2022
Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer.
2 Aug, 2022 | 11:58h | UTC
Review | Treatment of acute kidney injury in cancer patients.
2 Aug, 2022 | 11:43h | UTCTreatment of acute kidney injury in cancer patients – Clinical Kidney Journal
Related:
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the Global Burden of Disease.
1 Aug, 2022 | 12:09h | UTC
Cohort Study | Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.
1 Aug, 2022 | 12:03h | UTCCommentary: Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ – AJMC
Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.
1 Aug, 2022 | 12:04h | UTCClinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
‼️ Patients with low-risk (pT1b-pT2a) #melanoma may still develop high-risk sentinel node metastases ➡️ https://t.co/cBVdpR6xrG #JCO #melsm @marc_moncrieff pic.twitter.com/TW0WHp5brA
— Journal of Clinical Oncology (@JCO_ASCO) July 27, 2022
M-A | Endoscopic resection versus surgery in the treatment of early gastric cancer.
1 Aug, 2022 | 11:56h | UTC
Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.
1 Aug, 2022 | 11:48h | UTCPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)